COCA
In patients with out-of-hospital cardiac arrest, does calcium compared with placebo, improve sustained return of spontaneous circulation?
Continue reading »Category: Summaries
A category to collect all the summaries, so that they can be used in menus and widgets. Please don’t expand this – “Specialties” and “Special Topics” have been created as a custom category sets for the clinical topics.
SILENCE
In patients near end of life, does subcutaneous scopolamine butylbromide compared with placebo, reduce the incidence of death rattle?
Continue reading »SNOCAT
Effect of Out-of-Hospital Sodium Nitrite on Survival to Hospital Admission After Cardiac Arrest: A Randomized Clinical Trial Kim @uwcardiology. JAMA. 2021 January 12;325(2):138-145. doi: 10.1001/jama.2020.24326. Clinical Question In patients with out-of-hospital cardiac arrest, does sodium nitrite, compared with placebo, improve survival to hospital admission? Background Out-of-hospital cardiac arrest continues to have a high risk of morbidity and mortality Nitrate therapy […]
Continue reading »VAM-IHCA
Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest: A Randomized Clinical Trial Anderson et al. JAMA 2021. doi:10.1001/jama.2021.16628 Clinical Question In adult patients suffering an in-hospital cardiac arrest (IHCA) does the use of vasopressin and methylprednisolone compared to a placebo result in increased rates of return of spontaneous circulation (ROSC)? […]
Continue reading »COAST
In hypoxic African children (oxygen saturations of between 80 and 91%) with pneumonia, does oxygen therapy reduce mortality when compared with a permissive hypoxia (no oxygen) strategy?
In severely hypoxic children (oxygen saturations less than 80%), does high-flow nasal therapy reduce mortality when compared with low-flow oxygen therapy?
COVERT MI
In patients who present with an acute STEMI and are referred for percutaneous coronary intervention (PCI), does colchicine in comparsion with placebo reduce myocardial injury?
Continue reading »RECOVERY REGEN-COV
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial @PeterHorby. medRxiv pre-print 2021 doi: https://doi.org/10.1101/2021.06.15.21258542 Clinical Question In hospitalised patients with COVID-19, does the addition of monoclonal antibodies REGEN-COV (carsirivimab & imdevimab) to standard care, compared with standard care alone, improve 28 day mortality? Background Monoclonal antibodies have been shown to be […]
Continue reading »The REST Trial
In mechanically ventilated patients with acute hypoxaemic respiratory failure, does lowering tidal volume using extracorporeal carbon dioxide removal, compared with conventional low tidal volume ventilation, improve day 90 all-cause mortality?
Continue reading »COVID STEROID 2
In patients with severe COVID, does 12mg dexamethasone vs 6mg dexamethasone increase the number of days alive without life support at 28 days?
Continue reading »COV-BARRIER
In hospitalised adult patient with COVID-19, does baricitinib compared with placebo decrease a composite outcome of progression of illness and mortality?
Continue reading »